Why Aurinia’s new Lupkynis trial could change the lupus nephritis treatment sequence
Discover how Aurinia’s PRESERVE study could reshape lupus nephritis care by combining Lupkynis with three major biologic therapies.
Pharma & Biotech
Pharma & Biotech
Why Brii Bio’s BRII-179 sequencing data could reshape hepatitis B combination treatment
See how Brii Bio’s Phase 2b hepatitis B data support BRII-179 immune priming while durability and Phase 3 risks remain.
Pharma & Biotech
Contineum Therapeutics paper sharpens PIPE-791 case, but Phase 2 IPF data remain decisive
Discover why Contineum Therapeutics’ PIPE-791 paper strengthens the LPAR1 case while Phase 2 IPF data remain the decisive clinical test.
Pharma & Biotech
Fizurex advances toward human trials as Steel Therapeutics completes pivotal safety study
Discover how Steel Therapeutics’ Fizurex toxicology milestone could reshape anal fissure treatment as the program advances toward an FDA IND.
Medical Devices & Diagnostics
Why MedX Health’s SkinSecure could reshape how skin treatment efficacy is measured
See how MedX Health’s SkinSecure could reshape collagen endpoints in skin trials and which validation risks researchers must watch.
Pharma & Biotech
Could Verastem Oncology’s KRAS G12D bet change the pancreatic cancer treatment race?
Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.
Pharma & Biotech
Why EMA orphan status gives Zai Lab’s zoci more than a regulatory credibility boost
Find out how Zai Lab’s zocilurtatug pelitecan could reshape DLL3-targeted cancer therapy as development risks remain.
Pharma & Biotech
Could BMN 333 help BioMarin reset expectations in achondroplasia treatment?
Find out how BioMarin’s VOXZOGO and BMN 333 data could reshape rare bone disorder treatment as competition intensifies.
Pharma & Biotech
Takeda’s narcolepsy data reveal why orexin agonists are becoming a neuroscience priority
Find out how Takeda’s oveporexton data could reshape narcolepsy type 1 care as approval, safety and access questions loom.
Pharma & Biotech
Soleno Therapeutics VYKAT XR data strengthens long-term case in Prader-Willi syndrome
Find out how Soleno Therapeutics’ VYKAT XR data could reshape hyperphagia treatment in Prader-Willi syndrome.